Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

27.51 -0.12 (-0.43%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

June 11, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

June 02, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

May 29, 2025

From uniQure Inc.

Via GlobeNewswire

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗

May 09, 2025

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024.

Via Stocktwits

Earnings Outlook For uniQure ↗

May 08, 2025

Via Benzinga

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 09, 2025

From uniQure Inc.

Via GlobeNewswire

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

uniQure to Announce First Quarter 2025 Financial Results

May 05, 2025

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~

From uniQure Inc.

Via GlobeNewswire

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

April 17, 2025

Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Which stocks are moving on Thursday? ↗

April 17, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic ↗

April 17, 2025

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

Via Stocktwits

Topics Bankruptcy

There are notable gap-ups and gap-downs in today's session. ↗

April 17, 2025

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗

April 17, 2025

Via Benzinga

What's going on in today's pre-market session ↗

April 17, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? ↗

April 17, 2025

uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses.

Via Benzinga

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

April 17, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

February 27, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗

February 07, 2025

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

Via Benzinga

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

February 03, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

January 30, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Pricing of its Public Offering

January 08, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Proposed Public Offering

January 07, 2025

From uniQure Inc.

Via GlobeNewswire

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? ↗

December 15, 2024

Via The Motley Fool

S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings ↗

December 10, 2024

Via Benzinga

Topics Stocks

Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings ↗

December 10, 2024

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday ↗

December 10, 2024

Via Benzinga

Dow Falls 150 Points; Oracle Posts Downbeat Results ↗

December 10, 2024

Via Benzinga

Topics Stocks

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗

December 10, 2024

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.